OneOncology

Business

Cencora Raises Full-Year Outlook on Strong Q1, Bolstered by OneOncology Acquisition

Healthcare distributor Cencora (COR) posted robust first-quarter results, driven by its U.S. Healthcare Solutions segment and the recent majority stake purchase in OneOncology. The company lifted its revenue and operating income guidance for fiscal 2026, signaling confidence in its physician practice support strategy despite some international margin pressure.

Business

Cencora Raises Full-Year Outlook on Strong Q1 Performance, OneOncology Acquisition

Healthcare distribution giant Cencora (NYSE: COR) kicked off its fiscal 2026 with robust growth, reporting a 12% increase in adjusted operating income and a 9% rise in adjusted EPS. Bolstered by the completion of its OneOncology acquisition and sustained strength in its U.S. specialty pharmaceuticals business, the company has raised its full-year guidance.

Business

Cencora's Q4 Revenue Falls Short of Forecasts Despite Steady Growth

Healthcare distribution giant Cencora (NYSE: COR) reported quarterly revenue that missed Wall Street expectations, though sales increased 5.5% year-over-year to $85.93 billion. Adjusted earnings per share of $4.08 slightly surpassed consensus estimates.